Human FcRn Transgenic Mice for Pharmacokinetic Evaluation of Therapeutic Antibodies
- 6 May 2016
- book chapter
- Published by Springer Nature
- Vol. 1438, 103-114
Abstract
Therapeutic monoclonal antibodies are widely recognized to be a most promising means to treat an increasing number of human diseases, including cancers and autoimmunity. To a large extent, the efficacy of monoclonal antibody treatment is because IgG antibodies have greatly extended persistence in vivo. However, conventional rodent models do not mirror human antibody pharmacokinetics. The key molecule responsible for the extended persistence antibodies is the major histocompatibility complex class I family Fc receptor, FcRn. We describe human FcRn transgenic mouse models and how they can be exploited productively for the preclinical pharmacokinetic evaluation of therapeutic antibodies.Keywords
This publication has 24 references indexed in Scilit:
- Enhanced antibody half-life improves in vivo activityNature Biotechnology, 2010
- Molecular engineering and design of therapeutic antibodiesCurrent Opinion in Immunology, 2008
- Engineering therapeutic monoclonal antibodiesImmunological Reviews, 2008
- FcRn: the neonatal Fc receptor comes of ageNature Reviews Immunology, 2007
- Perspective – FcRn transports albumin: relevance to immunology and medicineTrends in Immunology, 2006
- The Major Histocompatibility Complex–related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its LifespanJournal of Experimental Medicine, 2003
- EtanerceptDrugs, 1999
- Crystal structure of the complex of rat neonatal Fc receptor with FcNature, 1994
- Crystal structure at 2.2 Å resolution of the MHC-related neonatal Fc receptorNature, 1994
- The class I major histocompatibility complex related Fc receptor shows pH-dependent stability differences correlating with immunoglobulin binding and releaseBiochemistry, 1993